Our study found that HR488B could prevent E2F1 from releasing from E2F1/Rb/HDAC1 complex by inhibiting the phosphorylation of Rb protein, providing a theoretical basis for HR488B treating CRC patients with high expression of E2F1 (Fig. 6). This evidence concerns the gene RB1 and colorectal carcinoma.